Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 77 resultados

EUCLIDEAN: Acquired adaptive immune cell dysfunction and restoration in chronic hepatitis B UNIVERSITA VITASALUTE SAN RAFFAELE tramitó un HORIZON EUROPE: ERC-2023-ADG This proposal aims to investigate the development of dysfunctional adaptive immune cells during chronic hepatitis B virus (HBV) infection an...
2024-09-01 - 2029-08-31 | Financiado

UNION: UnderstandiNg fraIlty tOwards a future of healthy ageiNg With falling birth rates and increasing life expectancy we are an ageing society. 20% of boys and 25% of girls born in 2019 are expected to...
2024-07-01 - 2028-12-31 | Financiado

EUCLIDEAN: Acquired adaptive immune cell dysfunction and restoration in chronic hepatitis B UNIVERSITA VITASALUTE SAN RAFFAELE tramitó un HORIZON EUROPE: ERC-2023-ADG This proposal aims to investigate the development of dysfunctional adaptive immune cells during chronic hepatitis B virus (HBV) infection an...
2024-06-28 - 2029-08-31 | Financiado

MIRACLE: Integrated multi angle research and training network to eradicate leukemia minimal residual disease An estimated 300,000 new cases of leukemia are diagnosed each year globally. The most common form of acute leukemia is acute myeloid leukemi...
2024-06-28 - 2028-11-30 | Financiado

TETRIS: Risk assessment Tools for severe side Effects after breasT Radiotherapy radiation safety through b... Radiation protection and safety measures are essential to ensure adequate quality & safety in radiotherapy (RT). Side effects are systematic...
2024-06-28 - 2027-09-30 | Financiado

TREATLIVMETS: Treating Liver Metastasis UNIVERSITA VITASALUTE SAN RAFFAELE participó en un HORIZON EUROPE: ERC-2023-SyG Liver metastases commonly develop in up to 50% of patients with various cancer types. The most common cancer that metastasizes to the liver...
2024-06-11 - 2030-06-30 | Financiado

easi-IPMN: Early Inflammatory Signatures of IPMN Progression UNIVERSITA VITASALUTE SAN RAFFAELE tramitó un HORIZON EUROPE: ERC-2023-POC Pancreatic Ductal Adenocarcinoma (PDAC) is a lethal cancer with rising global incidence and poor survival rates. Early PDAC diagnosis is ham...
2024-04-23 - 2025-10-31 | Financiado

MEET: Missions: Engagement and Education for Tomorrow UNIVERSITA VITASALUTE SAN RAFFAELE participó en un HORIZON EUROPE: HORIZON-MSCA-2023-CITIZENS-01 MEET - Missions: Engagement and Education for Tomorrow - is the proposed European Researchers Night event and Researcher at School programme...
2024-04-22 - 2026-04-30 | Financiado

CONNASHION: Vascular Control of NASH Progression UNIVERSITA VITASALUTE SAN RAFFAELE tramitó un HORIZON EUROPE: ERC-2023-COG Non-alcoholic steato-hepatitis (NASH) is a major risk factor for hepatocellular carcinoma (HCC), the 6th most common cause of cancer-related...
2024-04-04 - 2029-09-30 | Financiado

B-Path: Breath Pathogen Detection (B-Path): Establishing Exhaled Breath Aerosol (XBA) sampling for diagnosis... UNIVERSITA VITASALUTE SAN RAFFAELE participó en un HORIZON EUROPE: HORIZON-HLTH-2023-TOOL-05 Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of €s in...
2023-12-11 - 2028-06-30 | Financiado

GREMLIN: The role of GPCRs and homing molecules in the control and regionalization of mucosal immunity. UNIVERSITA VITASALUTE SAN RAFFAELE tramitó un HORIZON EUROPE: ERC-2023-STG Mucosal immunity is essential to preserve homeostasis and for pathogen control within the gut and the airways. The emerging dogma of immune...
2023-11-20 - 2028-12-31 | Financiado

MEFHISTO: Decoding and targeting the PGE2-MEF2A axis in tumor-associated macrophages UNIVERSITA VITASALUTE SAN RAFFAELE tramitó un HORIZON EUROPE: ERC-2022-COG Inflammation is a complex spectrum of processes whose outcomes range from cell killing to tissue regeneration. In this context, a major goal...
2023-05-30 - 2028-08-31 | Financiado

METHYLOMIC: DNA methylation markers to predict treatment success of biologicals in Crohn’s disease. UNIVERSITA VITASALUTE SAN RAFFAELE participó en un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid...
2022-11-24 - 2026-12-31 | Financiado

OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence UNIVERSITA VITASALUTE SAN RAFFAELE participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado

UNITE4TB: ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS UNIVERSITA VITASALUTE SAN RAFFAELE participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Current anti-tuberculosis (TB) drug regimens face serious limitations at times of increasing antimicrobial drug resistance. Fortunately, for...
2021-06-29 - 2028-05-31 | Financiado

UNISR